Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis

Kidney International

Volumn 63, Issue 5, 2003, Pages 1687-1696

  Liu, Hua ^a   Baliga, Radhakrishna ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Apopotosis; Cisplatin; Cytochrome P450 2E1; Heme oxygenase 1; Knockout mice; Nephrotoxicity; Reactive oxygen metabolites

Indexed keywords

BLEOMYCIN; CISPLATIN; CREATININE; CYTOCHROME P450 2E1; DNA FRAGMENT; HEME OXYGENASE 1; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IRON; REACTIVE OXYGEN METABOLITE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG INDUCED DISEASE; HISTOPATHOLOGY; IMMUNOELECTRON MICROSCOPY; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY MICROSOME; KIDNEY PROXIMAL TUBULE; KIDNEY SLICE; KNOCKOUT MOUSE; MOUSE; NEPHROTOXICITY; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING;

EID: 0037406266     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00908.x     Document Type: Article

References (56)

1. LEBWOHL D, CANETTA R: Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur J Cancer 34:1522-1534, 1998
2. RIES F, KLASTERSKY J: Nephrotoxicity induced by cancer chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis 8:368-379, 1986
3. SAFIRSTEIN R, WINSTON J, GOLDSTEIN M, et al: Cisplatin nephrotoxicity. Am J Kidney Dis 8:356-367, 1986
4. BALIGA R, ZHANG Z, BALIGA M, et al: In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. Kidney Int 53:394-401, 1998
5. DAVIS CA, NICK HS, AGARWAL A: Manganese superoxide dismutase attenuates cisplatin-induced renal injury: importance of superoxide. J Am Soc Nephrol 12:2683-2690, 2001
6. LIEBERTHAL W, TRIACA V, LEVINE J: Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. Am J Physiol 270 (4 Pt 2):F700-F708, 1996
7. LAU AH: Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int 56:1295-1298, 1999
8. GONZALEZ FJ: The molecular biology of cytochrome P450s. Pharmacol Rev 40:243-288, 1988
9. KUTHAN H, TSUJI H, GRAF H, ULLRICH V: Generation of superoxide anion as a source of hydrogen peroxide in a reconstituted monooxygenase system. FEBS Lett 91:343-345, 1978
10. NORDBLOM GD, COON MJ: Hydrogen peroxide formation and stoichiometry of hydroxylation reactions catalyzed by highly purified liver microsomal cytochrome P-450. Arch Biochem Biophys 180:343-347, 1977
11. BALIGA R, ZHANG Z, BALIGA M, SHAH SV: Evidence for cytochrome P-450 as a source of catalytic iron in myoglobinuric acute renal failure. Kidney Int 49:362-369, 1996
12. BALIGA R, ZHANG Z, BALIGA M, et al: Role of cytochrome P-450 as a source of catalytic iron in cisplatin-induced nephrotoxicity. Kidney Int 54:1562-1569, 1998
13. BYSANI GK, KENNEDY TP, KY N, et al: Role of cytochrome P-450 in reperfusion injury of the rabbit lung. J Clin Invest 86:1434-1441, 1990
14. PALLER MS, JACOB HS: Cytochrome P-450 mediates tissue-damaging hydroxyl radical formation during reoxygenation of the kidney. Proc Natl Acad Sci USA 91:7002-7006, 1994
15. LIU H, BIGLER SA, HENEGAR JR, BALIGA R: Cytochrome P450 2B1 mediates oxidant injury in puromycin induced nephrotic syndrome. Kidney Int 62:868-876, 2002
16. GUENGERICH FP, KIM DH, IWASAKI M: Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179, 1991
17. LUCAS D, FAREZ C, BARDOU LG, VAISSE J, et al: Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam Clin Pharmacol 12:553-558, 1998
18. MANDL J, BANHEGYI G, KALAPOS MP, GARZO T: Increased oxidation and decreased conjugation of drugs in the liver caused by starvation. Altered metabolism of certain aromatic compounds and acetone. Chem Biol Interact 96:87-101, 1995
19. MCCARVER DG, BYUN R, HINES RN, et al: A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 152:276-281, 1998
20. DAI Y, RASHBA-STEP J, CEDERBAUM AI: Stable expression of human cytochrome P4502E1 in HepG2 cells: Characterization of catalytic activities and production of reactive oxygen intermediates. Biochemistry 32:6928-6937, 1993
21. EKSTROM G, INGELMAN-SUNDBERG M: Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1). Biochem Pharmacol 38:1313-1319, 1989
22. LEE SS, BUTERS JT, PINEAU T, et al: Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271:12063-12067, 1996
23. EL-DEIRY WS, TOKINO T, VELCULESCU VE, et al: WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
24. GUTTERIDGE JM, ROWLEY DA, HALLIWELL B: Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Biochem J 199:263-265, 1981
25. GUTTERIDGE JM, ROWLEY DA, HALLIWELL B: Superoxide-dependent formation by hydroxyl radicals and lipid peroxidation in the presence of iron salts. Biochem J 206:605-609, 1982
26. UEDA N, BALIGA R, SHAH SV: Role of "catalytic" iron in an animal model of minimal change nephrotic syndrome. Kidney Int 49:370-373, 1996
27. KUTTY RK, NAGINENI CN, KUTTY G, et al: Increased expression of heme oxygenase-1 in human retinal pigment epithelial cells by transforming growth factor-beta. J Cell Physiol 159:371-378, 1994
28. TRAKSHEL GM, KUTTY RK, MAINES MD: Purification and characterization of the major constitutive form of testicular heme oxygenase. The noninducible isoform. J Biol Chem 261:11131-11137, 1986
29. BRADD SJ, DUNN MJ: Analysis of membrane proteins by Western blotting and enhanced chemiluminescence. Methods Mol Biol 19:211-218, 1993
30. HSU SM, RAINE L, FANGER H: A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol 75:734-738, 1981
31. GARTEL AL, YE X, GOUFMAN E, et al: Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA 98:4510-4515, 2001
32. ZHANG JG, LINDUP WE: Cisplatin-induced changes in adenine nucleotides in rat kidney slices: amelioration by tiopronin and procaine. J Pharm Pharmacol 49:1136-1140, 1997
33. ROSENKRANZ AR, SCHMALDIENST S, STUHLMEIER KM, et al: A microplate assay for the detection of oxidative products using 2′,7′-dichlorofluorescin-diacetate. J Immunol Methods 156:39-45, 1992
34. BALIGA R, ZHANG Z, SHAH SV: Role of cytochrome P-450 in hydrogen peroxide-induced cytotoxicity to LLC-PK1 cells. Kidney Int 50:1118-1124, 1996
35. RAMACHANDRA S, STUDZINSKI GP: Morphological and biochemical criteria of apoptosis, in Cell Growth and Apoptosis, edited by STUDZINSKI GP, New York, Oxford University Press, 1995, pp 119-141
36. DENNERY PA: Regulation and role of heme oxygenase in oxidative injury. Curr Top Cell Regul 36:181-199, 2000
37. HIRT DL, JACOBSON HR: Functional effects of cytochrome P450 arachidonate metabolites in the kidney. Semin Nephrol 11:148-155, 1991
38. CARROLL MA, BALAZY M, HUANG DD, et al: Cytochrome P450-derived renal HETEs: Storage and release. Kidney Int 51:1696-1702, 1997
39. BALIGA R, UEDA N, WALKER PD, SHAH SV: Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 29:465-477, 1997
40. LIU H, BALIGA M, BALIGA R: Effect of cytochrome P450 2E1 inhibitors on cisplatin-induced cytotoxicity to renal proximal tubular epithelial cells. Anticancer Res 22:863-868, 2002
41. NATH KA, BALLA G, VERCELLOTTI GM, et al: Induction of heme oxygenase is a rapid, protective response in rhabdomyolysis in the rat. J Clin Invest 90:267-270, 1992
42. AGARWAL A, BALLA J, ALAM J, et al: Induction of heme oxygenase in toxic renal injury: A protective role in cisplatin nephrotoxicity in the rat. Kidney Int 48:1298-1307, 1995
43. SHIRAISHI F, CURTIS LM, TRUONG L, et al: Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis. Am J Physiol 278:F726-F736, 2000
44. INGUAGGIATO P, GONZALEZ-MICHACA L, CROATT AJ, et al: Cellular overexpression of heme oxygenase-1 up-regulates p21 and confers resistance to apoptosis. Kidney Int 60:2181-2191, 2001
45. BISSELL DM, HAMMAKER LE: Cytochrome P-450 heme and the regulation of hepatic heme oxygenase activity. Arch Biochem Biophys 176:91-102, 1976
46. UEDA N, KAUSHAL GP, SHAH SV: Apoptotic mechanisms in acute renal failure. Am J Med 108:403-415, 2000
47. KLUCK RM, BOSSY-WETZEL E, GREEN DR, NEWMEYER DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science 275:1132-1136, 1997
48. REED JC: Cytochrome c: Can't live with it - Can't live without it. Cell 91:559-562, 1997
49. TAKEDA M, KOBAYASHI M, SHIRATO I, et al: Cisplatin-induced apoptosis of immortalized mouse proximal tubule cells is mediated by interleukin-1 beta converting enzyme (ICE) family of proteases but inhibited by overexpression of Bcl-2. Arch Toxicol 71:612-621, 1997
50. LI P, NIJHAWAN D, BUDIHARDJO I, et al: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479-489, 1997
51. FINKEL T: Oxygen radicals and signaling. Curr Opin Cell Biol 10:248-253, 1998
52. RASHBA-STEP J, CEDERBAUM AI: Generation of reactive oxygen intermediates by human liver microsomes in the presence of NADPH or NADH. Mol Pharmacol 45:150-157, 1994
53. BONDY SC, NADERI S: Contribution of hepatic cytochrome P450 systems to the generation of reactive oxygen species. Biochem Pharmacol 48:155-159, 1994
54. LABAER J, GARRETT MD, STEVENSON LF, et al: New functional activities for the p21 family of CDK inhibitors. Genes Dev 11:847-862, 1997
55. 1 cyclin-dependent kinases. Cell 75:805-816, 1993
56. MEGYESI J, SAFIRSTEIN RL, PRICE PM: Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. J Clin Invest 101:777-782, 1998